Abanoquil, a new alpha-1 adrenoceptor antagonist. In vitro and in vivo effect on erectile tissue

Giraldi, Annamaria; Wyllie, Michael G.; Wagner, Gorm

doi:10.1038/sj.ijir.3900505

Cited by 4 publications

(1 citation statement)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a similar study by Giraldi et al. [34] the α1‐adrenoceptor antagonist abanoquil produced both a relaxant effect (contracted tissue strips) and an erectile response (when injected intracavernosally). In these studies there was also priapism leading to long‐lasting erections.…”

Section: Discussionmentioning

confidence: 81%

Alfuzosin attenuates erectile dysfunction in rats with partial bladder outlet obstruction

et al. 2008

View full text Add to dashboard Cite

pressure, and total ICP (area under the curve). Organ-bath studies were performed on corpus cavernosum smooth muscle (CCSM) strips. Nitric oxide synthase (NOS) expression was determined immunohistochemically (IHC) for neuronal (n)NOS and by Western blot analysis for endothelial (e) and inducible (i) NOS protein. RESULTSRats with PBOO showed lower erectile responses than controls. Maximum electrical field stimulation-mediated and endothelium-dependent acetylcholineinduced relaxations and contractile responses to phenylephrine were significantly reduced in CCSM strips from the PBOO group. The NO donor sodium nitroprusside completely relaxed CCSM from rats in all groups. IHC analyses showed decreased expression of nNOS in PBOO groups compared with controls; by contrast, protein expression of eNOS and iNOS was increased. Alfuzosin-treatment partially attenuated functional and molecular changes in penises of PBOO rats. CONCLUSIONRats with PBOO show ED, most likely due to altered NOS expression and NO bioavailability. The α -adrenoreceptor antagonist alfuzosin reversed this ED by altering sympathetic tone, increasing NOinduced relaxation and augmenting blood flow in the penis. This study suggests a rationale for further clinical trials using combinations of α -adrenoceptor antagonists and phosphodiesterase-5 inhibitors in patients with ED and lower urinary tract symptoms. KEYWORDSrat model, partial bladder outlet obstruction, nitric oxide synthase, alfuzosin, erectile function Study Type -Therapy (RCT) Level of Evidence 1b OBJECTIVETo determine how partial bladder outlet obstruction (PBOO) in a rat model affects erectile function, and whether an uroselective α 1-adrenoceptor antagonist, alfuzosin (Sanofi-Aventis, Paris, France) attenuates any erectile dysfunction (ED). MATERIALS AND METHODSAdult male Sprague-Dawley rats (120) were randomized into four groups: 1, shamoperated; 2, alfuzosin-treated; 3, PBOO; and 4, alfuzosin-treated with PBOO. Groups 3 and 4 were subjected to PBOO for 6 weeks by ligation of the urethra, while groups 2 and 4 rats received daily oral alfuzosin (10 mg/day) for 6 weeks. In vivo erectile responses were monitored by evaluating ratios of intracavernosal pressure (ICP)/mean arterial

show abstract

Section: Discussionmentioning

confidence: 81%

Alfuzosin attenuates erectile dysfunction in rats with partial bladder outlet obstruction

et al. 2008

View full text Add to dashboard Cite

show abstract

Andrology

Pryor¹

2000

Current Opinion in Urology

View full text Add to dashboard Cite

Intracavernous Pharmacotherapy for Erectile Dysfunction

Bella

Brock

2004

ENDO

View full text Add to dashboard Cite

With the advent of phosphodiesterase type-5 inhibition as oral therapy, intracavernous injection of vasoactive agents has been relegated to second-line therapy for most patients with erectile dysfunction. However, the future of this category of agents remains bright as an ever-expanding number and combination of agents in use and under investigation will likely make intracavernous injection more appealing as greater efficacy, tolerability, and more rapid onset is attained. In this article, functional anatomy and physiology of human penile erection is reviewed, as are current clinical vasoactive agents including prostaglandin E-1, papaverine, and phentolamine. Emerging therapies discussed include guanylate cyclase activators, potassium channel openers, nitric oxide donors, vasoactive intestinal polypeptide, calcitonin gene-related peptide, selective alpha-1 receptor antagonists, and gene therapy. Ongoing research continues to define new roles for this effective and safe technique, which has withstood the test of time, restoring erectile function among patients with diverse ED etiologies and a variety of co-morbidities.

show abstract

Abanoquil, a new alpha-1 adrenoceptor antagonist. In vitro and in vivo effect on erectile tissue

Cited by 4 publications

References 9 publications

Alfuzosin attenuates erectile dysfunction in rats with partial bladder outlet obstruction

Alfuzosin attenuates erectile dysfunction in rats with partial bladder outlet obstruction

Andrology

Intracavernous Pharmacotherapy for Erectile Dysfunction

Contact Info

Product

Resources

About